22.69
price up icon4.85%   1.05
 
loading
Arvinas Inc stock is traded at $22.69, with a volume of 729.87K. It is up +4.85% in the last 24 hours and down -16.30% over the past month. Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$21.64
Open:
$21.59
24h Volume:
729.87K
Relative Volume:
1.33
Market Cap:
$1.56B
Revenue:
$71.30M
Net Income/Loss:
$-354.80M
P/E Ratio:
-4.059
EPS:
-5.59
Net Cash Flow:
$-356.00M
1W Performance:
-10.46%
1M Performance:
-16.30%
6M Performance:
-31.78%
1Y Performance:
+4.23%
1-Day Range:
Value
$21.17
$22.71
1-Week Range:
Value
$21.17
$25.75
52-Week Range:
Value
$20.28
$53.08

Arvinas Inc Stock (ARVN) Company Profile

Name
Name
Arvinas Inc
Name
Phone
203-535-1456
Name
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Name
Employee
445
Name
Twitter
@ArvinasInc
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
ARVN's Discussions on Twitter

Compare ARVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ARVN 22.69 1.56B 71.30M -354.80M -356.00M -5.59
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-24 Downgrade Citigroup Buy → Neutral
Feb-01-24 Initiated Goldman Buy
Dec-19-23 Upgrade Wells Fargo Equal Weight → Overweight
Dec-06-23 Upgrade Jefferies Hold → Buy
Nov-20-23 Upgrade Guggenheim Neutral → Buy
Oct-23-23 Upgrade Wedbush Neutral → Outperform
Jun-26-23 Resumed Oppenheimer Outperform
Jan-12-23 Downgrade Guggenheim Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-22 Initiated Barclays Overweight
Jun-21-22 Initiated Jefferies Hold
May-09-22 Downgrade Wedbush Outperform → Neutral
Apr-28-22 Initiated Credit Suisse Outperform
Apr-06-22 Initiated Morgan Stanley Equal-Weight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Overweight
Jan-19-22 Initiated Goldman Buy
Dec-07-21 Initiated Cowen Outperform
Oct-14-21 Initiated SVB Leerink Outperform
Sep-30-21 Initiated Stifel Buy
Sep-09-21 Initiated BofA Securities Buy
May-21-21 Initiated UBS Buy
Apr-21-21 Initiated Truist Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Dec-14-20 Upgrade Oppenheimer Perform → Outperform
Jun-01-20 Upgrade Citigroup Neutral → Buy
May-12-20 Initiated Oppenheimer Perform
Dec-19-19 Initiated H.C. Wainwright Buy
Nov-25-19 Initiated Guggenheim Buy
Oct-24-19 Upgrade Goldman Neutral → Buy
Sep-25-19 Initiated Wedbush Outperform
Sep-12-19 Initiated BMO Capital Markets Outperform
Aug-06-19 Initiated Cantor Fitzgerald Overweight
Jun-05-19 Downgrade Citigroup Buy → Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Oct-22-18 Initiated Citigroup Buy
Oct-22-18 Initiated Goldman Neutral
Oct-22-18 Initiated Piper Jaffray Overweight
View All

Arvinas Inc Stock (ARVN) Latest News

pulisher
Nov 20, 2024

Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire

Nov 20, 2024
pulisher
Nov 20, 2024

Unveiling 4 Analyst Insights On Arvinas - Benzinga

Nov 20, 2024
pulisher
Nov 20, 2024

Arvinas shares target cut to $62 on delayed trial data - Investing.com

Nov 20, 2024
pulisher
Nov 19, 2024

Arvinas reports delay in breast cancer trial results - Investing.com India

Nov 19, 2024
pulisher
Nov 19, 2024

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

Pfizer, Arvinas delay late-stage trial for breast cancer therapy - Seeking Alpha

Nov 19, 2024
pulisher
Nov 18, 2024

Stephens Begins Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 12, 2024

Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com

Nov 12, 2024
pulisher
Nov 10, 2024

How the (ARVN) price action is used to our Advantage - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 07, 2024

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Nov 07, 2024
pulisher
Nov 07, 2024

Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 04, 2024

Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World

Nov 04, 2024
pulisher
Nov 01, 2024

Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada

Oct 31, 2024
pulisher
Oct 31, 2024

Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 29, 2024

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com

Oct 29, 2024
pulisher
Oct 29, 2024

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat

Oct 29, 2024
pulisher
Oct 25, 2024

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance

Oct 25, 2024
pulisher
Oct 23, 2024

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey

Oct 23, 2024
pulisher
Oct 23, 2024

Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Oct 23, 2024
pulisher
Oct 22, 2024

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com

Oct 22, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Oct 22, 2024

Arvinas Inc Stock (ARVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):